Moran Wealth Management LLC grew its stake in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 79.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,204 shares of the company’s stock after buying an additional 21,811 shares during the period. Moran Wealth Management LLC owned approximately 0.11% of ARK Genomic Revolution ETF worth $1,300,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently modified their holdings of ARKG. JPMorgan Chase & Co. increased its position in shares of ARK Genomic Revolution ETF by 30.6% in the 4th quarter. JPMorgan Chase & Co. now owns 5,149,454 shares of the company’s stock valued at $149,180,000 after buying an additional 1,205,541 shares in the last quarter. Morgan Stanley lifted its holdings in ARK Genomic Revolution ETF by 42.2% during the fourth quarter. Morgan Stanley now owns 4,025,965 shares of the company’s stock worth $116,632,000 after acquiring an additional 1,193,795 shares in the last quarter. BNP Paribas Financial Markets grew its stake in ARK Genomic Revolution ETF by 49.7% in the fourth quarter. BNP Paribas Financial Markets now owns 3,514,980 shares of the company’s stock valued at $101,829,000 after acquiring an additional 1,167,558 shares during the period. Wells Fargo & Company MN grew its stake in ARK Genomic Revolution ETF by 29.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,287,390 shares of the company’s stock valued at $37,296,000 after acquiring an additional 290,301 shares during the period. Finally, LPL Financial LLC increased its holdings in shares of ARK Genomic Revolution ETF by 9.0% in the fourth quarter. LPL Financial LLC now owns 824,961 shares of the company’s stock worth $23,899,000 after acquiring an additional 68,267 shares in the last quarter.
ARK Genomic Revolution ETF Trading Down 3.2%
Shares of BATS:ARKG traded down $1.40 during trading on Tuesday, hitting $42.17. 843,724 shares of the company’s stock traded hands, compared to its average volume of 2,994,927. ARK Genomic Revolution ETF has a 52 week low of $22.73 and a 52 week high of $44.47. The company has a 50-day moving average price of $33.84 and a 200-day moving average price of $30.85.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
See Also
- Five stocks we like better than ARK Genomic Revolution ETF
- GE Vernova’s Power Surge Turns the Grid Into an AI Trade
- Orbiting Capital: Lawmakers Buy SpaceX Ahead of Index Inclusion
- Big Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?
- 3 Stocks With Solid Yields and Sustainabale Payouts Boost Dividends Once Again
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
